Nurix Therapeutics (NRIX) Announces Extension of Strategic Collaboration with Sanofi (SNY) to Develop Novel Targeted Protein Degraders of STAT6

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Nurix Therapeutics (NRIX) Announces Extension of Strategic Collaboration with Sanofi (SNY) to Develop Novel Targeted Protein Degraders of STAT6

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

April 9, 2024 7:00 AM EDT

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation

Nurix anticipates nominating a clinical candidate within the first year of the extension

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of... More